Papers
7
Total Citations
1,015
H-Index
6
About
Vivek Venkatramani is a leading urologic oncologist whose work has fundamentally reshaped the evidence base for surgical management of bladder and kidney cancers. He is best known as a principal investigator of the landmark RAZOR trial, the first multi-institutional, phase 3 randomized study to demonstrate that robot-assisted radical cystectomy is non-inferior to open surgery for progression-free survival in bladder cancer patients. This seminal work, published in *The Lancet* and cited over 760 times, has directly influenced global surgical guidelines. Dr. Venkatramani has extended this impact through subsequent analyses from the RAZOR cohort, providing critical data on 3-year survival outcomes (115 citations), health-related quality of life, and recovery of functional independence—showing that robotic approaches can offer meaningful advantages in patient-reported outcomes. His research also includes influential studies on partial nephrectomy utilization and a forward-looking review on the future of urology. By rigorously comparing surgical techniques, Dr. Venkatramani has empowered surgeons and patients with high-quality evidence to guide treatment decisions, cementing his role as a key figure in the shift toward minimally invasive urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6Urovision 2020: The future of urology11 citations · 2015
- 7